CR9465A - Compuestos mejorados farmacocineticamente - Google Patents
Compuestos mejorados farmacocineticamenteInfo
- Publication number
- CR9465A CR9465A CR9465A CR9465A CR9465A CR 9465 A CR9465 A CR 9465A CR 9465 A CR9465 A CR 9465A CR 9465 A CR9465 A CR 9465A CR 9465 A CR9465 A CR 9465A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmacocinetically
- improved compounds
- rock2
- methods
- rock1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
La presente invencion se relaciona con inhibidores de ROCK1 y ROCK2 y con metodos para modular las propiedades farmacocineticas y/o farmacodinamicas de esos compuestos. Tambien se proporcionan metodos para inhibir ROCK1 y ROCK2 que son utiles para el tratamiento de la enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66516505P | 2005-03-25 | 2005-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9465A true CR9465A (es) | 2008-06-19 |
Family
ID=37054004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9465A CR9465A (es) | 2005-03-25 | 2001-10-23 | Compuestos mejorados farmacocineticamente |
Country Status (21)
Country | Link |
---|---|
US (6) | US8357693B2 (es) |
EP (1) | EP1865958B1 (es) |
JP (2) | JP2008534518A (es) |
KR (1) | KR20080081122A (es) |
CN (1) | CN101208094B (es) |
AU (1) | AU2006230159A1 (es) |
BR (1) | BRPI0622285A2 (es) |
CA (1) | CA2602254C (es) |
CR (1) | CR9465A (es) |
EA (1) | EA022875B1 (es) |
EC (1) | ECSP077836A (es) |
ES (1) | ES2549397T3 (es) |
GE (1) | GEP20105029B (es) |
IL (1) | IL186299A0 (es) |
MX (1) | MX2007011859A (es) |
NO (1) | NO20075145L (es) |
NZ (1) | NZ562083A (es) |
SG (1) | SG155163A1 (es) |
UA (1) | UA96126C2 (es) |
WO (1) | WO2006105081A2 (es) |
ZA (1) | ZA200708858B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
EP2314295B1 (en) | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
JP2009534458A (ja) | 2006-04-26 | 2009-09-24 | キャンサー・リサーチ・テクノロジー・リミテッド | アミノ−エチル−アミノ−アリール(aeaa)化合物およびそれらの使用 |
AU2007287024A1 (en) * | 2006-08-24 | 2008-02-28 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
EP2099458A4 (en) * | 2006-12-01 | 2011-05-11 | Harvard College | COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS |
MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
RU2010101416A (ru) * | 2007-06-19 | 2011-07-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Профилактическое/лекарственное средство от рака |
KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
MX2011002365A (es) | 2008-09-02 | 2011-04-04 | Novartis Ag | Derivados de picolinamida como inhibidres de cinasa. |
CA2747417C (en) | 2009-01-08 | 2017-01-03 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
CA2755095A1 (en) * | 2009-03-09 | 2010-09-16 | Surface Logix, Inc. | Rho kinase inhibitors |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
BRPI1014956B8 (pt) | 2009-04-22 | 2021-05-25 | Resverlogix Corp | agentes anti-inflamatórios |
US8658676B2 (en) * | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
JP5992049B2 (ja) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | 置換されたキナゾリノンのための経口速放性製剤 |
AU2013264831B2 (en) | 2012-05-21 | 2016-04-21 | Novartis Ag | Novel ring-substituted N-pyridinyl amides as kinase inhibitors |
JP6187460B2 (ja) * | 2012-06-21 | 2017-08-30 | 大正製薬株式会社 | ピリドピリミジン−4−オン誘導体 |
CA2926478C (en) * | 2012-10-05 | 2022-05-24 | Kadmon Corporation, Llc | Rho kinase inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9695179B2 (en) | 2013-03-14 | 2017-07-04 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
CN109851617B (zh) | 2013-08-23 | 2022-08-16 | 润新生物公司 | 化学实体、组合物和方法 |
EP3270694A4 (en) | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
CN107708739A (zh) * | 2015-06-24 | 2018-02-16 | 日东电工株式会社 | 可电离化合物、组合物及它们的用途 |
US10508106B2 (en) | 2015-11-25 | 2019-12-17 | Convergene Llc | Bicyclic BET bromodomain inhibitors and uses thereof |
EP4006035B1 (en) * | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
US11071735B2 (en) | 2017-04-28 | 2021-07-27 | Kadmon Corporation, Llc | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors |
WO2019001572A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
WO2019000682A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
JP2020532551A (ja) | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Rho関連コイルドコイルキナーゼ(ROCK)阻害剤としてのビニルヘテロ環 |
EP4219495A1 (en) | 2018-02-06 | 2023-08-02 | Ideaya Biosciences, Inc. | Ahr modulators |
EP3782987A4 (en) | 2018-04-18 | 2021-05-19 | Medshine Discovery Inc. | BENZOPYRAZOLE COMPOUND AS A RHO CINEMA INHIBITOR |
US20220002266A1 (en) * | 2018-11-09 | 2022-01-06 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof |
JP7252417B2 (ja) | 2019-10-18 | 2023-04-04 | メッドシャイン ディスカバリー インコーポレイテッド | Rhoキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法 |
CN114746412A (zh) * | 2019-12-27 | 2022-07-12 | 广东东阳光药业有限公司 | Kd-025的新晶型及其制备方法 |
WO2022020850A1 (en) | 2020-07-22 | 2022-01-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of belumosudil and belumosudil salts |
WO2022042666A1 (zh) * | 2020-08-28 | 2022-03-03 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
WO2022170864A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州科睿思制药有限公司 | Belumosudil甲磺酸盐的晶型及其制备方法和用途 |
CN114573566B (zh) * | 2021-03-04 | 2023-05-30 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
WO2023285706A1 (en) | 2021-07-16 | 2023-01-19 | Sandoz Ag | Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt |
TW202404602A (zh) | 2022-04-19 | 2024-02-01 | 美商凱德蒙有限責任公司 | 移植後肺部病症的治療方法 |
WO2024000060A1 (en) * | 2022-06-30 | 2024-01-04 | Apotex Inc | Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease |
WO2024015068A1 (en) | 2022-07-14 | 2024-01-18 | Kadmon Corporation, Llc | Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease |
CA3178096A1 (en) | 2022-07-14 | 2024-01-14 | Kadmon Corporation, Llc | Methods of administering belumosudil for treatment of chronic graft versus host disease |
WO2024015065A1 (en) | 2022-07-14 | 2024-01-18 | Kadmon Corporation, Llc | Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations |
WO2024015066A1 (en) | 2022-07-14 | 2024-01-18 | Kadmon Corporation, Llc | Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors |
CN115385899B (zh) * | 2022-09-08 | 2024-04-02 | 药康众拓(江苏)医药科技有限公司 | ROCK2抑制剂belumosudil的氘代药物及用途 |
WO2024063770A1 (en) | 2022-09-21 | 2024-03-28 | Kadmon Corporation, Llc | Liquid formulation of belumosudil |
WO2024100601A1 (en) | 2022-11-11 | 2024-05-16 | Assia Chemical Industries Ltd. | Solid state forms of belumosudil and processes for preparation thereof |
WO2024118556A1 (en) | 2022-11-29 | 2024-06-06 | Kadmon Corporation, Llc | Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide |
WO2024124084A1 (en) | 2022-12-09 | 2024-06-13 | Kadmon Corporation, Llc | Methods of administering belumosudil for treatment of multiple myeloma |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ1598A3 (cs) * | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
AU738620B2 (en) | 1996-08-12 | 2001-09-20 | Mitsubishi Pharma Corporation | Pharmaceutical agent containing Rho kinase inhibitor |
TWI284642B (en) * | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
EP1270570B1 (en) * | 2000-03-16 | 2006-05-31 | Mitsubishi Pharma Corporation | Amide compounds and use thereof |
US6924292B2 (en) * | 2000-03-23 | 2005-08-02 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
US6699665B1 (en) | 2000-11-08 | 2004-03-02 | Surface Logix, Inc. | Multiple array system for integrating bioarrays |
ATE325795T1 (de) | 2001-03-23 | 2006-06-15 | Bayer Corp | Rho-kinase inhibitoren |
JP4320705B2 (ja) | 2001-03-23 | 2009-08-26 | バイエル コーポレイション | Rhoキナーゼ阻害剤 |
WO2003012392A2 (en) | 2001-07-27 | 2003-02-13 | Surface Logix, Inc. | Resealable and sealable devices for biochemical assays |
EP1560939A4 (en) | 2001-08-27 | 2007-04-25 | Surface Logix Inc | IMMOBILIZATION OF BIOLOGICAL MOLECULES ON SURFACES COATED WITH MONOSLAYS |
JP2003221386A (ja) * | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
DE10162435A1 (de) | 2001-12-19 | 2003-07-17 | Joerg Lahann | Verfahren zur Erzeugung von Oberflächenbeschichtungen, die die Adsorption von Proteinen bzw. die Adhäsion von Bakterien und/oder Zellen vermindern |
GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
CA2506799A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
GB0301016D0 (en) * | 2003-01-16 | 2003-02-19 | Univ London | Treatment of benign prostatic hyperplasia |
US20040266755A1 (en) | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
US20070275961A1 (en) * | 2003-06-04 | 2007-11-29 | Vernalis (Cambridge) Limited. | Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine |
WO2005020921A2 (en) * | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
UA90502C2 (ru) * | 2005-02-18 | 2010-05-11 | Сьёрфейс Лоджикс, Инк. | Имидазотриазиноновые соединения и фармацевтическая композиция, которая их содержит |
JP2008530246A (ja) * | 2005-02-18 | 2008-08-07 | サーフェイス ロジックス,インコーポレイティド | 機能性残基又は官能基を含む薬物動態学的に改善された化合物、及び上述の化合物を含む医薬組成物の製造方法 |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
AU2007287024A1 (en) * | 2006-08-24 | 2008-02-28 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
-
2001
- 2001-10-23 CR CR9465A patent/CR9465A/es not_active Application Discontinuation
-
2006
- 2006-03-27 EA EA200702048A patent/EA022875B1/ru active IP Right Revival
- 2006-03-27 ZA ZA200708858A patent/ZA200708858B/xx unknown
- 2006-03-27 AU AU2006230159A patent/AU2006230159A1/en not_active Abandoned
- 2006-03-27 UA UAA200711701A patent/UA96126C2/ru unknown
- 2006-03-27 KR KR1020077024624A patent/KR20080081122A/ko not_active Application Discontinuation
- 2006-03-27 BR BRPI0622285-4A patent/BRPI0622285A2/pt not_active IP Right Cessation
- 2006-03-27 CA CA2602254A patent/CA2602254C/en active Active
- 2006-03-27 SG SG200905004-8A patent/SG155163A1/en unknown
- 2006-03-27 US US11/887,218 patent/US8357693B2/en active Active
- 2006-03-27 GE GEAP200610335A patent/GEP20105029B/en unknown
- 2006-03-27 JP JP2008503293A patent/JP2008534518A/ja not_active Withdrawn
- 2006-03-27 WO PCT/US2006/011271 patent/WO2006105081A2/en active Application Filing
- 2006-03-27 CN CN200680018211.1A patent/CN101208094B/zh active Active
- 2006-03-27 NZ NZ562083A patent/NZ562083A/en not_active IP Right Cessation
- 2006-03-27 ES ES06748799.1T patent/ES2549397T3/es active Active
- 2006-03-27 EP EP06748799.1A patent/EP1865958B1/en active Active
- 2006-03-27 MX MX2007011859A patent/MX2007011859A/es not_active Application Discontinuation
-
2007
- 2007-09-25 IL IL186299A patent/IL186299A0/en unknown
- 2007-10-10 NO NO20075145A patent/NO20075145L/no not_active Application Discontinuation
- 2007-10-23 EC EC2007007836A patent/ECSP077836A/es unknown
-
2012
- 2012-12-14 US US13/715,644 patent/US8916576B2/en active Active
-
2014
- 2014-12-23 US US14/581,746 patent/US9440961B2/en active Active
-
2015
- 2015-07-03 JP JP2015134574A patent/JP5956661B2/ja active Active
-
2017
- 2017-04-24 US US15/495,019 patent/US20180072710A1/en not_active Abandoned
-
2018
- 2018-07-19 US US16/040,245 patent/US10570123B2/en active Active
-
2020
- 2020-02-24 US US16/799,076 patent/US20210017166A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9465A (es) | Compuestos mejorados farmacocineticamente | |
CR7182A (es) | Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
CR9528A (es) | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion | |
CY2015003I1 (el) | Φαρμακευτικες συνθεσεις για θεραπεια καρκινου | |
DE60142921D1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
ECSP066635A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares | |
ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
BR9914044A (pt) | ésteres tetrahidropirido | |
DE602004020070D1 (de) | Thienopyrimidin-derivate als kaliumkanal-inhibitoren | |
ATE438618T1 (de) | Inhibitoren von humanem adam-10 | |
MXPA04006266A (es) | Pirimidotriazinas como inhibidores de fosfatasa. | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
PT1060175E (pt) | Inibidores de triptase | |
CY1110043T1 (el) | 2-αμινοβενζουλ παραγωγα | |
DE60329326D1 (de) | Tace inhibitoren | |
BRPI0415355A (pt) | triarilimidazóis | |
CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
UY27394A1 (es) | Pedidos con actividad anti- angiogéna. | |
ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
NO20005548D0 (no) | Mykobakterieinhibitorer | |
PT1077694E (pt) | Produtos terapeuticos de arilnitrona para o tratamento da doenca inflamatoria dointestino | |
DK1551850T3 (da) | 2"-oxo-voruscharin og derivater deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |